Home » Stocks » Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. (TEVA)

Stock Price: $12.66 USD 0.86 (7.29%)
Updated Aug 5, 2020 4:00 PM EDT - Market closed
After-hours: $12.52 -0.14 (-1.11%) Aug 5, 6:06 PM

Stock Price Chart

Key Info

Market Cap 13.87B
Revenue (ttm) 17.10B
Net Income (ttm) -825.00M
Shares Out 1.10B
EPS (ttm) -0.76
PE Ratio n/a
Forward PE 4.65
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $12.66
Previous Close $11.80
Change ($) 0.86
Change (%) 7.29%
Day's Open 12.50
Day's Range 12.01 - 12.75
Day's Volume 20,591,025
52-Week Range 6.07 - 13.76

More Stats

Market Cap 13.87B
Enterprise Value 38.58B
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 1.10B
Float 1.09B
EPS (basic) -0.75
EPS (diluted) -0.76
FCF / Share 0.38
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 3.02%
Payout Ratio n/a
Shares Short 21.87M
Short Ratio 2.42
Short % of Float n/a
Beta 1.66
PE Ratio n/a
Forward PE 4.65
P/FCF Ratio 33.10
PS Ratio 0.81
PB Ratio 0.93
Revenue 17.10B
Operating Income -467.00M
Net Income -825.00M
Free Cash Flow 419.00M
Net Cash -24.71B
Net Cash / Share -22.56
Gross Margin 44.08%
Operating Margin -2.73%
Profit Margin -4.90%
FCF Margin 2.45%
ROA 3.27%
ROE -5.78%
ROIC -1.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (23)

Buy 4
Overweight 1
Hold 15
Underweight 1
Sell 2

Analyst Consensus: Overweight

Price Target

(-7.58% downside)
Current: $12.66
Target: 11.70
*Average 12-month price target from 18 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-7.57%-16.39%-0.23%11.45%-3.06%-0.21%-0.01%10.95%13.59%-
Gross Profit7,5368,29610,61611,65311,35611,05610,70710,6529,5159,065
Operating Income-520-1,928-18,6821,3853,1863,9511,6492,2053,1093,871
Net Income-999-2,150-16,2653291,5883,0551,2691,9632,7593,331
Shares Outstanding1,0911,0211,016955855853849872890896
Earnings Per Share-0.91-2.35-
EPS Growth----96.15%-48.88%138.93%-33.78%-27.18%-15.8%-
Dividend Per Share--0.721.361.
Dividend Growth---46.91%8.11%8.17%6.7%34.57%2.53%17.91%-
Operating Cash Flow7482,4462,2253,8905,5425,1273,2374,5724,1344,136
Capital Expenditures-525-651-874-901-772-929-1,031-1,104-1,053-710
Free Cash Flow2231,7951,3512,9894,7704,1982,2063,4683,0813,426
Cash & Equivalents1,9751,7829639886,9462,2261,0382,8791,0961,248
Total Debt27,34228,91632,47535,8009,94310,32712,19114,71814,5166,881
Net Cash / Debt-25,367-27,134-31,512-34,812-2,997-8,101-11,153-11,839-13,420-5,633
Book Value13,97214,70717,35933,33729,76923,31322,56522,76822,19521,947
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Teva Pharmaceutical Industries Ltd.
Country Israel
Employees 40,039
CEO Kåre Schultz

Stock Information

Ticker Symbol TEVA
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: TEVA


Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.